10-K · February 25, 2026
Schrödinger reports scale and continued software-driven growth with total revenue of $255.9 million in 2025 and software revenue of $199.5 million (up 11% YoY). The company is expanding enterprise adoption (ACV $198.5…
Earnings analysis · 10-Q
SDGR earnings analysis
Filed May 5, 2026 · Our reading of the company's report
The latest report
Schrödinger reported Q1 2026 financial results with revenues of $58.6 million, a slight 2% decline year-over-year, while net loss increased to $60.0 million, compared to $59.8 million in Q1 2025. The company beat…
Read full summary
Schrödinger reported Q1 2026 financial results with revenues of $58.6 million, a slight 2% decline year-over-year, while net loss increased to $60.0 million, compared to $59.8 million in Q1 2025. The company beat initial EPS estimates by posting -$0.81 per share, attributing the decrease in revenue primarily to a decline in software sales. Management reaffirms annual contract value targets between $218 million to $228 million, indicating ongoing expectations of growth despite recent revenue trends.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.81
- Gross margin
- 50.4%
- Segment
- Software
- Segment
- Drug Discovery
- Segment
- Contribution
What stood out
-
Revenue Decline Stabilizes
Q1 2026 revenue was $58.6M, a 2% decrease year-over-year from $59.6M.
-
EPS Beat Estimates
Reported EPS of -$0.81, beating estimates of -$0.57.
-
Drug Discovery Segment Growth
Drug discovery revenues surged to $22.9M, a 124% increase from $10.2M in Q1 2025.
-
ACV Growth
Annual contract value grew to $28.4M in Q1 2026 from $25.4M in Q1 2025.
-
Cost Control Improvements
Operating expenses decreased by 4% year-over-year from Q1 2025.
-
Strong Cash Position
As of March 31, 2026, cash and equivalents totaled $406.4M.
What to watch
-
High Net Loss Continues
Net loss increased to $60.0M in Q1 2026 from $59.8M in Q1 2025.
-
Declining Software Revenue
Software revenue dropped to $35.6M, a 21% decrease from $45.0M in Q1 2025.
-
Contribution Revenue Slump
Contribution revenue decreased by 97%, falling to $148K from $4.3M in Q1 2025.
Management's outlook
Management maintained ACV expectations of $218M-228M for fiscal year 2026 with anticipated growth.
Earlier filings 4
10-Q · August 6, 2025
Schrödinger reported Q2 revenue of $54,759,000, up from $47,334,000 in Q2 2024, and GAAP net loss per share improved to $(0.59) from $(0.74). Gross margin contracted to 47.8% (from 66.2% a year ago) as cost of revenues…
10-Q · May 1, 2024
Schrödinger reported Q1 revenues of $36.6M (three months ended March 31, 2024) versus $64.8M a year ago, driven by a sharp decline in drug discovery revenue while software revenue was modestly higher. The company posted…
10-Q · May 4, 2022
Schrödinger reported Q1 revenues of $48.663M, up 51.5% year-over-year from $32.127M, driven by software ($33.081M) and a sharp increase in drug discovery revenue ($15.582M). Gross profit rose to $27.983M (gross margin…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.